Annexon, Inc. (ANNX) News
Track canonical SquawkNews coverage tagged to ANNX, Annexon, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision OutcomesARCHER II is the First Pivotal Trial Designed to Demons
NEWS | Sep 24, 2026, 12:03 PM UTC
L
ANNX - Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
ANNX - Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
NEWS | Sep 24, 2026, 12:01 PM UTC
M
Annexin treats first NEXUS expanded-cohort patient in Germany
Annexin Pharmaceuticals treated the first NEXUS expanded-cohort patient in Germany with anti-VEGF followed by vanexin. The patient completed Day 15 follow-up with no adverse events.
EQUITY | Sep 17, 2026, 06:31 AM UTC
L
ANNX - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 08:05 PM UTC
L
Annexin Pharmaceuticals to Present at Investing in Life Science on September 22
The 4th edition of Investing in Life Science takes place on September 22 in Stockholm. Anders Haegerstrand, CEO will present Annexin Pharmaceuticals to specialist life science investors and potential strategic partners.I
EQUITY | Sep 10, 2026, 07:01 AM UTC
L
ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation
Late-stage programs in GBS and GA are advancing, with strong clinical data and regulatory filings in progress. The GA study's unique focus on functional vision and mechanistic differentiation positions it for significant
EQUITY | Sep 09, 2026, 02:30 PM UTC
L
ANNX late-stage GBS and GA programs advancing; US, Europe filings due soon
Late-stage programs in GBS and GA are advancing, with clinical efficacy and trial design described as robust. Regulatory filings in the US and Europe are expected soon, per TradingView News.
EQUITY | Sep 09, 2026, 01:51 PM UTC
L
Annexon to participate in September investor conferences
Annexon, Inc. said Douglas Love, Esq. will participate in upcoming September investor conferences.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
ANNX - Annexon to Participate in Upcoming September Investor Conferences
ANNX - Annexon to Participate in Upcoming September Investor Conferences
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
JPM maintains Annexon overweight and raises price target to $14
JP Morgan maintains Annexon at overweight and raises its price target to $14.00 per share from $10.00.
EQUITY | Sep 01, 2026, 06:44 PM UTC
L
Annexon (ANNX) reports inducement grants under Nasdaq Rule 5635(c)(4)
Annexon (ANNX) reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 17, 2026, 08:05 PM UTC
L
ANNX Reports Q2 2026 Financial Results
ANNX reports second quarter 2026 financial results and business updates
EARNINGS | Aug 12, 2026, 10:05 AM UTC
M
ANNX Expands Vonaprument Phase 3 Program
ANNX expands Vonaprument Phase 3 program in geographic atrophy
EQUITY | Aug 12, 2026, 10:00 AM UTC
H
Annexon Reports Positive Clinical Responses
Annexon's GBS FORWARD study shows positive responses
EQUITY | Aug 06, 2026, 12:00 PM UTC
H
Annexon secures $200M credit facility
Annexon gets $200M credit facility
EQUITY | Jul 30, 2026, 08:02 PM UTC
L
ANNX Initiated Underperform and $3 PT @ Citizens
ANNX Initiated Underperform and $3 PT @ Citizens
EQUITY | Jul 21, 2026, 12:04 PM UTC
L
ANNX PT raised from $11 to $25, maintains Buy @ Needham
ANNX PT raised from $11 to $25, maintains Buy @ Needham
EQUITY | Jul 15, 2026, 12:33 PM UTC
L
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Let
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
EQUITY | Jul 14, 2026, 08:14 PM UTC